Compare EPR Properties (EPR) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Natera Inc. Common Stock — how do they compare? EPR Properties trades at $54.64 (market cap $4.18B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 13.6× EPR Properties's market cap, and EPR Properties pays a 6.82% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 48 Days and Natera Inc. Common Stock for 0 Days on average.
| EPR | NTRA | |
|---|---|---|
Market Cap | $4.18B | $57.03B |
Volume | 699,137 | 1,131,157 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $425.64 |
52-Week Low | $48.71 | $179.42 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $7.69B | $56.18B |
Dividend Yield | 6.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $54.80, down 1.1% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The REIT shows strong profitability with a 91.41% gross margin and 37.66% net income margin, though net income dipped slightly in 2026. Recent news highlights its 6.5% dividend yield and focus on diversification beyond theaters into experiential properties, with Q3 2026 earnings due October 29, 2026.
The outlook is mixed: analyst consensus is a Buy with a $65.50 price target, implying ~20% upside, supported by a high yield and undervalued P/FFO. Risks include exposure to leisure and entertainment tenants, rising interest rates impacting financing costs, and the Q1 2026 earnings miss. Cash flow trends show a net outflow in 2026, warranting monitoring of dividend coverage.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
